Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance

被引：33
作者：
Hogan, Jonathan J. [1 ]
Weiss, Brendan M. [2 ]
机构：
[1] Univ Penn, Div Nephrol, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2016年 / 11卷 / 09期
关键词：
MULTIPLE-MYELOMA PATIENTS; CHRONIC LYMPHOCYTIC-LEUKEMIA; LENALIDOMIDE PLUS DEXAMETHASONE; MINIMAL RESIDUAL DISEASE; CHAIN DEPOSITION DISEASE; SINGLE-AGENT CARFILZOMIB; MANTLE-CELL LYMPHOMA; TERM-FOLLOW-UP; OPEN-LABEL; FLOW-CYTOMETRY;
D O I：
10.2215/CJN.03160316
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The monoclonal gammopathies of renal significance (MGRS) are a group of disorders characterized by monoclonal Ig deposition in the kidney, but are not associated with systemic lymphoma or overt multiple myeloma. The prevailing hypothesis is that the pathogenic paraproteins in MGRS are produced by underlying B cell or plasma cell clones. However, in the MGRS literature, the yield of detecting a clone has been variable, and progression to ESRD is common. Here, we present an "onco-nephrologic" approach to the MGRS disorders by highlighting recent advances in lymphoma and multiple myeloma that can be used in the evaluation and management of these patients.
引用
收藏
页码：1681 / 1691
页数：11
相关论文
共 65 条
  • [11] Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis
    Chen, Nionhang
    Lau, Henry
    Kon, Linghui
    Kumar, Gondi
    Zeldis, Jerome B.
    Knight, Robert
    Laskin, Oscar L.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (12) : 1466 - 1475
  • [12] High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
    Child, JA
    Morgan, GJ
    Davies, FE
    Owen, RG
    Bell, SE
    Hawkins, K
    Brown, J
    Drayson, MT
    Selby, PJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) : 1875 - 1883
  • [13] A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma
    de Tute, R. M.
    Jack, A. S.
    Child, J. A.
    Morgan, G. J.
    Owen, R. G.
    Rawstron, A. C.
    [J]. LEUKEMIA, 2007, 21 (09) : 2046 - U2
  • [14] The Efficacy and Safety of Lenalidomide Plus Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients With Impaired Renal Function
    Dimopoulos, Meletios
    Alegre, Adrian
    Stadtmauer, Edward A.
    Goldschmidt, Hartmut
    Zonder, Jeffrey A.
    de Castro, Carlos M.
    Masliak, Zvenyslava
    Reece, Donna
    Olesnyckyj, Marta
    Yu, Zhinuan
    Weber, Donna M.
    [J]. CANCER, 2010, 116 (16) : 3807 - 3814
  • [15] Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
    Dreyling, Martin
    Jurczak, Wojciech
    Jerkeman, Mats
    Silva, Rodrigo Santucci
    Rusconi, Chiara
    Trneny, Marek
    Offner, Fritz
    Caballero, Dolores
    Joao, Cristina
    Witzens-Harig, Mathias
    Hess, Georg
    Bence-Bruckler, Isabelle
    Cho, Seok-Goo
    Bothos, John
    Goldberg, Jenna D.
    Enny, Christopher
    Traina, Shana
    Balasubramanian, Sriram
    Bandyopadhyay, Nibedita
    Sun, Steven
    Vermeulen, Jessica
    Rizo, Aleksandra
    Rule, Simon
    [J]. LANCET, 2016, 387 (10020) : 770 - 778
  • [16] Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences
    Eve, Heather E.
    Carey, Sean
    Richardson, Sarah J.
    Heise, Carla C.
    Mamidipudi, Vidya
    Shi, Tao
    Radford, John A.
    Auer, Rebecca L.
    Bullard, Sheila H.
    Rule, Simon A. J.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (02) : 154 - 163
  • [17] How I treat monoclonal gammopathy of renal significance (MGRS)
    Fermand, Jean-Paul
    Bridoux, Frank
    Kyle, Robert A.
    Kastritis, Efstathios
    Weiss, Brendan M.
    Cook, Mark A.
    Drayson, Mark T.
    Dispenzieri, Angela
    Leung, Nelson
    [J]. BLOOD, 2013, 122 (22) : 3583 - 3590
  • [18] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    Fisher, Richard I.
    Bernstein, Steven H.
    Kahl, Brad S.
    Djulbegovic, Benjamin
    Robertson, Michael J.
    de Vos, Sven
    Epner, Elliot
    Krishnan, Amrita
    Leonard, John P.
    Lonial, Sagar
    Stadtmauer, Edward A.
    O'Connor, Owen A.
    Shi, Hongliang
    Boral, Anthony L.
    Goy, Andre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4867 - 4874
  • [19] Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An eastern cooperative oncology group study (E3A98)
    Gertz, MA
    Rue, M
    Blood, E
    Kaminer, LS
    Vesole, DH
    Greipp, PR
    [J]. LEUKEMIA & LYMPHOMA, 2004, 45 (10) : 2047 - 2055
  • [20] Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma
    Hobeika, Liliane
    Self, Sally E.
    Velez, Juan Carlos Q.
    [J]. BMC NEPHROLOGY, 2014, 15
1234567